AstraZeneca PLC (NASDAQ:AZN) Stake Lifted by Ieq Capital LLC

Ieq Capital LLC increased its stake in AstraZeneca PLC (NASDAQ:AZNGet Rating) by 8.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,703 shares of the company’s stock after acquiring an additional 2,175 shares during the period. Ieq Capital LLC’s holdings in AstraZeneca were worth $1,520,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in AZN. Andesa Financial Management Inc. lifted its stake in AstraZeneca by 1.9% during the second quarter. Andesa Financial Management Inc. now owns 8,867 shares of the company’s stock valued at $586,000 after purchasing an additional 165 shares during the last quarter. Seascape Capital Management lifted its stake in AstraZeneca by 0.4% during the second quarter. Seascape Capital Management now owns 45,744 shares of the company’s stock valued at $3,022,000 after purchasing an additional 185 shares during the last quarter. Roosevelt Investment Group LLC lifted its stake in AstraZeneca by 0.3% during the third quarter. Roosevelt Investment Group LLC now owns 72,000 shares of the company’s stock valued at $3,948,000 after purchasing an additional 187 shares during the last quarter. Columbia Asset Management lifted its stake in AstraZeneca by 2.0% during the third quarter. Columbia Asset Management now owns 9,708 shares of the company’s stock valued at $532,000 after purchasing an additional 189 shares during the last quarter. Finally, Community Bank & Trust Waco Texas lifted its stake in AstraZeneca by 4.1% during the third quarter. Community Bank & Trust Waco Texas now owns 4,843 shares of the company’s stock valued at $266,000 after purchasing an additional 191 shares during the last quarter. 16.42% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts recently commented on AZN shares. Guggenheim cut their target price on shares of AstraZeneca from £120 ($148.57) to £118 ($146.09) in a research note on Tuesday, October 11th. BMO Capital Markets assumed coverage on shares of AstraZeneca in a research report on Thursday, January 5th. They issued an “outperform” rating for the company. TheStreet upgraded shares of AstraZeneca from a “c” rating to an “a” rating in a research report on Monday, December 5th. Deutsche Bank Aktiengesellschaft upped their price target on shares of AstraZeneca from £120 ($148.57) to £130 ($160.95) in a research report on Thursday, December 15th. Finally, JPMorgan Chase & Co. upped their price target on shares of AstraZeneca from £125 ($154.76) to £135 ($167.14) in a research report on Tuesday, January 3rd. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, AstraZeneca presently has an average rating of “Hold” and a consensus target price of $9,510.67.

AstraZeneca Stock Down 2.0 %

AZN stock opened at $66.28 on Wednesday. AstraZeneca PLC has a 12-month low of $52.65 and a 12-month high of $72.12. The company has a current ratio of 0.81, a quick ratio of 0.61 and a debt-to-equity ratio of 0.65. The stock has a market cap of $205.39 billion, a P/E ratio of 98.93, a price-to-earnings-growth ratio of 1.24 and a beta of 0.53. The business has a 50 day moving average of $68.30.

AstraZeneca (NASDAQ:AZNGet Rating) last released its earnings results on Thursday, November 10th. The company reported $0.84 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.77 by $0.07. AstraZeneca had a net margin of 4.52% and a return on equity of 29.40%. The company had revenue of $10.98 billion during the quarter, compared to the consensus estimate of $10.98 billion. On average, research analysts anticipate that AstraZeneca PLC will post 3.33 EPS for the current year.

AstraZeneca Company Profile

(Get Rating)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

Featured Articles

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZNGet Rating).

Institutional Ownership by Quarter for AstraZeneca (NASDAQ:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.